Gandeeva Therapeutics

The primary market Gandeeva operates in is the pharmaceutical and biotechnology sector, with a specific focus on oncology, the branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. Their clients include pharmaceutical companies, research institutions, and healthcare providers who are looking for innovative treatments for challenging diseases.

Gandeeva's business model is built around its proprietary drug discovery platform. This platform uses AI and cryo-EM to identify and develop small molecules and engineered antibodies that can modulate protein interactions. One of their key innovations is the development of "proximity-inducing glues," which are small molecules that bring proteins closer together to achieve therapeutic effects. These glues are highly selective, meaning they target specific proteins involved in disease processes, thereby increasing the efficacy and reducing the side effects of treatments.

The company generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions. These partnerships often involve upfront payments, milestone payments, and royalties on sales of any successfully developed drugs. Additionally, Gandeeva may license its technology to other companies, providing another revenue stream.

In summary, Gandeeva Therapeutics is at the forefront of precision medicine, using AI and cryo-EM to develop groundbreaking therapies for some of the most challenging diseases, particularly in the field of oncology.